Merck & Co., (MRK) Gets Conditional Approval For EXZOLT CATTLE-CA1

Core Insights - Merck & Co., Inc. (NYSE:MRK) is identified as a promising investment opportunity, with an analyst from Guggenheim raising the price target from $104 to $122 while maintaining a Buy rating [1][3] - The company received conditional FDA approval for EXZOLT CATTLE-CA1, a topical solution aimed at treating infestations from New World screwworm larvae, with availability expected in Q1 2025 [2] - The increased price target is influenced by the potential revenue from Winrevair, which could exceed $5 billion annually if Phase 3 trials are successful [3] Company Overview - Merck & Co., Inc. is a global healthcare company focused on scientific innovation to develop health solutions, including prescription medicines, vaccines, biologic therapies, and animal health products [4]